ArticlePractical radiation oncology
Outcomes Following Combined Modality Treatment to the Primary Site in Select Patients With Metastatic Soft Tissue Sarcoma.
Article in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeSelect patients with metastatic soft tissue sarcoma (STS) may benefit from more aggressive treatment of their primary tumor. We report on the use of combined modality treatment (CMT) using preoperative radiation therapy (RT) followed by surgery to improve local control. METHODS AND MATERIALS: We retrospectively reviewed the data of 19 patients with metastatic STS consecutively treated at our institution with CMT between 2018 and 2023. All patients received moderately hypofractionated 40.05 Gy in 15 fractions followed by surgery. Patients were selected for CMT based on factors that were likely to predict longer survival despite having metastatic disease such as oligometastatic disease (≤5 lesions) and favorable response to systemic therapy.
resultsThe median size of the primary tumor was 7.6 cm (IQR, 4.4-12.7 cm). Fourteen patients (74%) received systemic therapy immediately before (n = 10) or after (n = 4) CMT. Seven patients (37%) underwent additional metastasis-directed local therapy following CMT to other sites. Pain reduction after CMT was documented in 89% of patients who presented with pain (n = 8 of 9). Median follow-up was 21 months. Two-year local recurrence-free survival, progression-free/distant recurrence-free survival, and overall/cancer-specific survival were 92%, 29%, and 65%, respectively. One patient (5%) had local recurrence. For patients who were not planned to have adjuvant systemic therapy, median systemic therapy-free survival was 15 months. The rate of wound complications within 120 days of surgery was 16%. No planned adjuvant therapy was delayed because of wound complications; all patients commenced systemic therapy within 3 months of surgery. The rate of late RT toxicities was 26%; there were no grade ≥3 late toxicities.
conclusionsFor properly selected patients with metastatic STS with good performance status and long expected survival, a CMT strategy for the primary tumor with moderately hypofractionated preoperative RT offers favorable local control, low toxicity, and pain mitigation without significant effect on systemic therapy resumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.